A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Public ClinicalTrials.gov record NCT04761198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).
Study identification
- NCT ID
- NCT04761198
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 76 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2021 (Actual)
- Primary completion
- Oct 30, 2023 (Actual)
- Completion
- Oct 30, 2023 (Actual)
- Last update posted
- Mar 17, 2025
2021 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mereo Investigator Site | Phoenix | Arizona | 85054 | — |
| Mereo Investigator Site | Greenbrae | California | 94904 | — |
| Mereo Investigator Site | Los Angeles | California | 90025 | — |
| Mereo Investigator Site | Jacksonville | Florida | 32224 | — |
| Mereo Investigator Site | Boston | Massachusetts | 02215 | — |
| Mereo Investigator Site | Ann Arbor | Michigan | 48109 | — |
| Mereo Investigator Site | Rochester | Minnesota | 55905 | — |
| Mereo Investigator Site | New York | New York | 10065 | — |
| Mereo Investigator Site | Durham | North Carolina | 27710 | — |
| Mereo Investigator Site | Oklahoma City | Oklahoma | 73104 | — |
| Mereo Investigator Site | Nashville | Tennessee | 37203 | — |
| Mereo Investigator Site | Houston | Texas | 77030 | — |
| Mereo Investigator Site | West Valley City | Utah | 84119 | — |
| Mereo Investigator Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04761198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04761198 live on ClinicalTrials.gov.